Thilo Krüger1, Stephan Oelenberg, Nadine Kaesler, Leon J Schurgers, Annette M van de Sandt, Peter Boor, Georg Schlieper, Vincent M Brandenburg, Bertalan C Fekete, Verena Veulemans, Markus Ketteler, Cees Vermeer, Willi Jahnen-Dechent, Jürgen Floege, Ralf Westenfeld. 1. From the Department of Nephrology, University Hospital of the Rheinisch Westfälische Technische Hochschule Aachen, Aachen, Germany (T.K., S.O., N.K., P.B., G.S., V.M.B., J.F.); Department of Biochemistry, Cardiovascular Research Institute CARIM, University of Maastricht, Maastricht, The Netherlands (L.J.S.); Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University Düsseldorf, Düsseldorf, Germany (A.M.v.d.S., V.V., R.W.); Department of Pathology, University Hospital of the RWTH Aachen, Aachen, Germany (P.B.); Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovakia (P.B.); 2nd Department of Medicine, Military Hospital Budapest, Budapest, Hungary (B.C.F.); Nephrology, Hospital Coburg, Coburg, Germany (M.K.); VitaK BV, Maastricht, The Netherlands (C.V.); Biointerface Laboratory, Helmholtz-Institute of Biomedical Engineering, Aachen, Germany (W.J-D.).
Abstract
OBJECTIVE: Vascular calcification is an independent risk factor for cardiovascular disease. Once thought to be a passive process, vascular calcification is now known to be actively prevented by proteins acting systemically (fetuin-A) or locally (matrix Gla protein). Warfarin is a vitamin K antagonist, widely prescribed to reduce coagulation by inhibiting vitamin K-dependent coagulation factors. Recently, it became clear that vitamin K antagonists also affect vascular calcification by inactivation of matrix Gla protein. Here, we investigated functional cardiovascular characteristics in a mouse model with warfarin-induced media calcification. APPROACH AND RESULTS: DBA/2 mice received diets with variable concentrations of warfarin (0.03, 0.3, and 3 mg/g) with vitamin K1 at variable time intervals (1, 4, and 7 weeks). Von Kossa staining revealed that warfarin treatment induced calcified areas in both medial layer of aorta and heart in a dose- and time-dependent fashion, which could be inhibited by simultaneous vitamin K2 treatment. With ongoing calcification, matrix Gla protein mRNA expression decreased, and inactive matrix Gla protein expression increased. TdT-mediated dUTP-biotin nick end labeling-positive apoptosis increased, and vascular smooth muscle cell number was concomitantly reduced by warfarin treatment. On a functional level, warfarin treatment augmented aortic peak velocity, aortic valve-peak gradient, and carotid pulse-wave velocity. CONCLUSION: Warfarin induced significant calcification with resulting functional cardiovascular damage in DBA/2 wild-type mice. The model would enable future researchers to decipher mechanisms of vascular calcification and may guide them in the development of new therapeutic strategies.
OBJECTIVE:Vascular calcification is an independent risk factor for cardiovascular disease. Once thought to be a passive process, vascular calcification is now known to be actively prevented by proteins acting systemically (fetuin-A) or locally (matrix Gla protein). Warfarin is a vitamin K antagonist, widely prescribed to reduce coagulation by inhibiting vitamin K-dependent coagulation factors. Recently, it became clear that vitamin K antagonists also affect vascular calcification by inactivation of matrix Gla protein. Here, we investigated functional cardiovascular characteristics in a mouse model with warfarin-induced media calcification. APPROACH AND RESULTS: DBA/2 mice received diets with variable concentrations of warfarin (0.03, 0.3, and 3 mg/g) with vitamin K1 at variable time intervals (1, 4, and 7 weeks). Von Kossa staining revealed that warfarin treatment induced calcified areas in both medial layer of aorta and heart in a dose- and time-dependent fashion, which could be inhibited by simultaneous vitamin K2 treatment. With ongoing calcification, matrix Gla protein mRNA expression decreased, and inactive matrix Gla protein expression increased. TdT-mediated dUTP-biotin nick end labeling-positive apoptosis increased, and vascular smooth muscle cell number was concomitantly reduced by warfarin treatment. On a functional level, warfarin treatment augmented aortic peak velocity, aortic valve-peak gradient, and carotid pulse-wave velocity. CONCLUSION:Warfarin induced significant calcification with resulting functional cardiovascular damage in DBA/2 wild-type mice. The model would enable future researchers to decipher mechanisms of vascular calcification and may guide them in the development of new therapeutic strategies.
Authors: G Schlieper; V Schwenger; A Remppis; T Keller; R Dechend; S Massberg; S Baldus; T Weinreich; G Hetzel; J Floege; F Mahfoud; D Fliser Journal: Internist (Berl) Date: 2017-05 Impact factor: 0.743
Authors: Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel Journal: Pediatr Nephrol Date: 2015-03-04 Impact factor: 3.714
Authors: O Mayer; J Seidlerová; P Wohlfahrt; J Filipovský; J Vaněk; R Cífková; J Windrichová; O Topolčan; M H J Knapen; N E A Drummen; C Vermeer Journal: J Hum Hypertens Date: 2015-05-28 Impact factor: 3.012
Authors: Britt Opdebeeck; Ellen Neven; José Luis Millán; Anthony B Pinkerton; Patrick C D'Haese; Anja Verhulst Journal: Bone Date: 2020-04-30 Impact factor: 4.398
Authors: Michael I McBurney; Jeffrey B Blumberg; Rebecca B Costello; Manfred Eggersdorfer; John W Erdman; William S Harris; Elizabeth J Johnson; Susan Hazels Mitmesser; Robert C Post; Deshanie Rai; Leon J Schurgers Journal: Nutrients Date: 2021-05-28 Impact factor: 5.717
Authors: Pietro Scicchitano; Marco Tucci; Maria Consiglia Bellino; Francesca Cortese; Annagrazia Cecere; Micaela De Palo; Francesco Massari; Pasquale Caldarola; Francesco Silvestris; Marco Matteo Ciccone Journal: Cardiovasc Drugs Ther Date: 2021-06 Impact factor: 3.727